Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
This study has been completed.
Sponsor:
Forest Laboratories
Information provided by:
Forest Laboratories
ClinicalTrials.gov Identifier:
NCT00334906
First received: June 6, 2006
Last updated: January 3, 2008
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer's Disease |
Drug: memantine HCl |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type |
Resource links provided by NLM:
Further study details as provided by Forest Laboratories:
Primary Outcome Measures:
- Efficacy
- Total brain atrophy on MRI
Secondary Outcome Measures:
- Other measures of brain atrophy on MRI, change from baseline in selected cognitive measures assessing multiple cognitive domains including memory, attention, motor-speed, auditory comprehension, and verbal fluency
- Safety
| Estimated Enrollment: | 75 |
| Study Start Date: | July 2005 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ambulatory male or female patients at least 50 years of age (females at least 2 years postmenopausal)
- A diagnosis of probable AD [according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA) criteria] of moderate severity [Mini-Mental State Examination score between 15 and 20, inclusive]
- On a stable dose of Food and Drug Administration (FDA)-approved acetylcholinesterase inhibitor
Exclusion Criteria:
- Current Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) Axis I disorder other than AD
- Previous imaging results not consistent with the diagnosis of AD
- Modified Hachinski Ischemia Score greater than 4
- Evidence of other neurologic disorders
- Inability to participate in MRI testing
- No clinically significant systemic disease
- A known or suspected history of alcohol or drug abuse in the past 10 years
- Taking excluded medication
- Previous treatment with commercial memantine
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00334906
Please refer to this study by its ClinicalTrials.gov identifier: NCT00334906
Locations
| United States, New Jersey | |
| Forest Laboratories | |
| Jersey City, New Jersey, United States, 07311 | |
Sponsors and Collaborators
Forest Laboratories
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00334906 History of Changes |
| Other Study ID Numbers: | MEM-MD-15 |
| Study First Received: | June 6, 2006 |
| Last Updated: | January 3, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Forest Laboratories:
|
memantine Alzheimer's disease MRI moderate Alzheimer's disease |
Additional relevant MeSH terms:
|
Alzheimer Disease Brain Diseases Central Nervous System Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Dementia Mental Disorders Nervous System Diseases Neurodegenerative Diseases Tauopathies Memantine Anti-Dyskinesia Agents |
Antiparkinson Agents Central Nervous System Agents Dopamine Agents Excitatory Amino Acid Agents Excitatory Amino Acid Antagonists Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses |
ClinicalTrials.gov processed this record on March 03, 2015